Physician
Oncology
Dr. Dianna L. Shipley, MD
|
|
Give Review
Dianna Shipley is an expert in the field of Oncology. She graduated from Joan C. Edwards School of Medicine. Dr. Dianna L. Shipley has written publications. She has 26 publications published with PubMed. The lastest paper is: 'High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.' She accepts Medicare payments and is registered with Medicare.gov.
Publications
- High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.
- Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium.
- Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung Cancer.
- Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung Cancer.
- A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced N...
- Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck:...
- Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer.
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer.
- A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer.
- Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung Cancer: a randomized pha...
- Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
- Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast Cancer.
- Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin Lymphoma: a pha...
- Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast Cancer: a phase II Trial of the Sarah Cannon Oncology...
- Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal Cancer.
- A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast Cancer.
- A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast Cancer.
- A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage...
- Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell Lymphoma who are poor candidates for R-CHOP chemotherapy:...
- Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory Carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology ...
- Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with Carcinoma of unknown primary site: a randomized, phase III ...
- A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung Cancer.
- Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung Cancer: a phase II/III study of the Minnie Pearl Cancer Research Netw...
- Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous Carcinoma of the head an...
- Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network.
Schools
Joan C Edwards School Of Medicine At Marshall University
W Penn Hospital
Charleston Area Mc
Nc Bapt Hospital Wake Forest University
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Oncology
Accepted Insurances
Education
-
Wake Forest University -
Charleston Area Medical Center - WVSOM -
Allegheny General Hospital - Western Pennsylvania Hospital -
Joan C. Edwards School of Medicine -
Marshall University Joan C. Edwards School of Medicine
Drug Facts
| NPI NUMBER | 1700810371 | |
| NPPES Provider LastName | SHIPLEY | |
| NPPES Provider FirstName | DIANNA | |
| NPPES Provider ZIPCode | 370663032 | |
| NPPES Provider State | TN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 2137.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 231.0 | |
| Percent Opioid Claims | 10.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1700810371 |
| Last Name Of The Provider | SHIPLEY |
| First Name Of The Provider | DIANNA |
| View All |
Similar Doctors
|
|
Dr. James D. Peyton, MD
 This Doctor is OpenDoctor Recommended.
|